iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics
ITOS Price/Volume Stats
| Current price | $10.80 | 52-week high | $18.24 |
| Prev. close | $10.60 | 52-week low | $8.20 |
| Day low | $10.55 | Volume | 140,900 |
| Day high | $10.90 | Avg. volume | 272,078 |
| 50-day MA | $11.37 | Dividend yield | N/A |
| 200-day MA | $11.17 | Market Cap | 387.10M |
ITOS Stock Price Chart Interactive Chart >
iTeos Therapeutics Inc. (ITOS) Company Bio
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.
Latest ITOS News From Around the Web
Below are the latest news stories about ITEOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ITOS as an investment opportunity.
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to TradeThe consensus price target hints at a 243.4% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
iTeos to Present at the Piper Sandler 35th Annual Healthcare ConferenceWATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET. A live webcast of the event will be av |
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom FisheriTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowThe mean of analysts' price targets for iTeos Therapeutics, Inc. (ITOS) points to a 304.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
ITOS Price Returns
| 1-mo | N/A |
| 3-mo | 2.18% |
| 6-mo | 7.36% |
| 1-year | -21.40% |
| 3-year | -54.83% |
| 5-year | N/A |
| YTD | -1.37% |
| 2023 | -43.93% |
| 2022 | -58.05% |
| 2021 | 37.67% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...